No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annual revenue · last 0 fiscal years
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Kardigan, Inc. (KARD) stock was $14.03 as of Oct 6, 2026, 10:00 AM EDT, down 7.94% from the previous close.
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist.
Biotechnology · Princeton, NJ
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-2.89
vs Estimate
$-0.64
Revenue
$0.00
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1KARD | $1.25B | $14.03 | -7.94% | N/A | N/A | N/A | N/A |
| 2CRON | $1.22B | $3.27 | +0.77% | +25.83% | -9.92% | +13.62% | vs KARD |
| 3MNKD | $1.22B | $3.83 | +0.13% | -33.55% | -4.18% | +1.97% | vs KARD |
| 4INNV | $1.22B | $9.00 | N/A | +79.14% | +5.55% | N/A | vs KARD |
| 5DMRA | $1.20B | $19.50 | -3.56% | +429.27% | -25.05% | N/A | vs KARD |
| 6AVBP | $1.33B | $28.46 | +0.67% | +43.20% | N/A | N/A | vs KARD |
forward FY estimate
N/A
vs Estimate
$0.00
Consensus Rating
Based on 4 analysts
Average Price Target
$42.25
+201.1% upside
Low
$37.00
Current
$14.03
High
$46.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.79 | $-0.79 | $-0.79 | 2 |
| Quarter ending Dec 2026 | $-0.99 | $-0.86 | $-0.72 | 2 |
| Quarter ending Mar 2027 | $-1.10 | $-1.10 | $-1.10 | 1 |
| Quarter ending Jun 2027 | $-1.15 | $-1.15 | $-1.15 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-5.14 | $-5.14 | $-5.14 | 2 |
| FY 2027 | $-3.35 | $-3.35 | $-3.35 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
